MedTrace Logo

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

NCT03575013 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-12-03

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of the combination of Avelumab, (a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody) in combination with a taxane chemotherapy (docetaxel) in patients with metastatic urothelial cancer who are either ineligible to receive cisplatin based chemotherapy, refractory to cisplatin in first line setting or have disease relapse after receiving cisplatin based chemotherapy within a year in the neoadjuvant or adjuvant setting.

Conditions

Interventions

DRUG

Avelumab

Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody

DRUG

Docetaxel

Docetaxel is a antineoplastic agent belonging to the taxoid family

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Iowa

    collaborator OTHER

  • Yousef Zakharia

    lead OTHER

Principal Investigators

  • Yousef Zakharia, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-29
Primary Completion
2021-12-15
Completion
2024-02-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03575013 on ClinicalTrials.gov